These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The molecular mechanisms of cellular tolerance to delta-opioid agonists. A minireview. Varga EV. Acta Biol Hung; 2003 Jul; 54(2):203-18. PubMed ID: 14535626 [Abstract] [Full Text] [Related]
3. Expression of alpha-transducin in Chinese hamster ovary cells stably transfected with the human delta-opioid receptor attenuates chronic opioid agonist-induced adenylyl cyclase superactivation. Rubenzik M, Varga E, Stropova D, Roeske WR, Yamamura HI. Mol Pharmacol; 2001 Nov; 60(5):1076-82. PubMed ID: 11641436 [Abstract] [Full Text] [Related]
4. Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adenylyl cyclase superactivation. Varga EV, Rubenzik M, Grife V, Sugiyama M, Stropova D, Roeske WR, Yamamura HI. Eur J Pharmacol; 2002 Sep 06; 451(1):101-2. PubMed ID: 12223234 [Abstract] [Full Text] [Related]
5. Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: adenylyl cyclase superactivation is independent of agonist-induced phosphorylation, desensitization, internalization, and down-regulation. Wang Y, Li JG, Huang P, Xu W, Liu-Chen LY. J Pharmacol Exp Ther; 2003 Dec 06; 307(3):1127-34. PubMed ID: 14557376 [Abstract] [Full Text] [Related]
6. Different regulation of human delta-opioid receptors by SNC-80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and endogenous enkephalins. Lecoq I, Marie N, Jauzac P, Allouche S. J Pharmacol Exp Ther; 2004 Aug 06; 310(2):666-77. PubMed ID: 15102931 [Abstract] [Full Text] [Related]
7. Mu opioid receptor mutant, T394A, abolishes opioid-mediated adenylyl cyclase superactivation. Wang H, Guang W, Barbier E, Shapiro P, Wang JB. Neuroreport; 2007 Dec 03; 18(18):1969-73. PubMed ID: 18007196 [Abstract] [Full Text] [Related]
8. Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80. Malatynska E, Wang Y, Knapp RJ, Waite S, Calderon S, Rice K, Hruby VJ, Yamamura HI, Roeske WR. J Pharmacol Exp Ther; 1996 Sep 03; 278(3):1083-9. PubMed ID: 8819489 [Abstract] [Full Text] [Related]
10. Phosphorylation of adenylyl cyclase VI upon chronic delta-opioid receptor stimulation. Varga EV, Stropova D, Rubenzik M, Waite S, Roeske WR, Yamamura HI. Eur J Pharmacol; 1999 Jan 08; 364(2-3):R1-3. PubMed ID: 9932732 [Abstract] [Full Text] [Related]
11. Short- and long-term regulation of adenylyl cyclase activity by delta-opioid receptor are mediated by Galphai2 in neuroblastoma N2A cells. Zhang L, Tetrault J, Wang W, Loh HH, Law PY. Mol Pharmacol; 2006 Jun 08; 69(6):1810-9. PubMed ID: 16525132 [Abstract] [Full Text] [Related]
12. Adenylyl cyclase type II activity is regulated by two different mechanisms: implications for acute and chronic opioid exposure. Schallmach E, Steiner D, Vogel Z. Neuropharmacology; 2006 Jun 08; 50(8):998-1005. PubMed ID: 16545401 [Abstract] [Full Text] [Related]
13. Agonist-specific down-regulation of the human delta-opioid receptor. Okura T, Varga EV, Hosohata Y, Navratilova E, Cowell SM, Rice K, Nagase H, Hruby VJ, Roeske WR, Yamamura HI. Eur J Pharmacol; 2003 Jan 10; 459(1):9-16. PubMed ID: 12505529 [Abstract] [Full Text] [Related]
14. Plasticity of adenylyl cyclase-related signaling sequelae after long-term morphine treatment. Shy M, Chakrabarti S, Gintzler AR. Mol Pharmacol; 2008 Mar 10; 73(3):868-79. PubMed ID: 18045853 [Abstract] [Full Text] [Related]
15. 3-(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-alkyl-N-arylbenzamides: potent, non-peptidic agonists of both the micro and delta opioid receptors. Bishop MJ, Garrido DM, Boswell GE, Collins MA, Harris PA, McNutt RW, O'Neill SJ, Wei K, Chang KJ. J Med Chem; 2003 Feb 13; 46(4):623-33. PubMed ID: 12570383 [Abstract] [Full Text] [Related]
17. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling. Szücs M, Boda K, Gintzler AR. J Pharmacol Exp Ther; 2004 Jul 13; 310(1):256-62. PubMed ID: 14996951 [Abstract] [Full Text] [Related]
18. Agonist Activity of the delta-antagonists TIPP and TIPP-psi in cellular models expressing endogenous or transfected delta-opioid receptors. Martin NA, Terruso MT, Prather PL. J Pharmacol Exp Ther; 2001 Jul 13; 298(1):240-8. PubMed ID: 11408548 [Abstract] [Full Text] [Related]
19. Adenosine A1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723. Musser B, Mudumbi RV, Liu J, Olson RD, Vestal RE. J Pharmacol Exp Ther; 1999 Feb 13; 288(2):446-54. PubMed ID: 9918544 [Abstract] [Full Text] [Related]
20. Chronic morphine acts via a protein kinase Cgamma-G(beta)-adenylyl cyclase complex to augment phosphorylation of G(beta) and G(betagamma) stimulatory adenylyl cyclase signaling. Chakrabarti S, Regec A, Gintzler AR. Brain Res Mol Brain Res; 2005 Jul 29; 138(1):94-103. PubMed ID: 15908039 [Abstract] [Full Text] [Related] Page: [Next] [New Search]